Alkermes Plc (ALKS) FinancialsALKSAlkermes Plc

Alkermes Plc (ALKS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is VIVITROL, accounting for 25.1% of total sales, equivalent to $124.45M. Other significant revenue streams include ARISTADA and LUMRYZ. Understanding this composition is critical for investors evaluating how ALKS navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Alkermes Plc maintains a gross margin of 75.67%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 9.03%, while the net margin is 0.10%. These profitability ratios, combined with a Return on Equity (ROE) of 3.85%, provide a clear picture of how effectively ALKS converts its operational activities into shareholder value.

In the context of the broader market, ALKS competes directly with industry leaders such as SYRE and TGTX. With a market capitalization of $8.20B, it holds a significant position in the sector. When comparing efficiency, ALKS's gross margin of 75.67% stands against SYRE's N/A and TGTX's 82.86%. Such benchmarking helps identify whether Alkermes Plc is trading at a premium or discount relative to its financial performance.

Alkermes reported a significant revenue increase of 27% year-over-year for Q2 2026, reaching $496 million. However, the company also reported a net loss of $66.48 million in Q1 2026 and only a minimal profit of $0.50 million in Q2 2026, indicating volatility in earnings.